Neuro-SysMed-seminar 22. april 2026
Velkommen til Neuro-SysMed sine månadlege seminar! Bli med i auditoriet i Armauer Hansens Hus kl. 11:30–13:00 (lunsj fra 11:30–12:00). Emnet denne gongen vil bli presentert frå Neuro-SysMeds ALS-node.
Forelesar
Ole-Bjørn Tysnes og Mari Klauset Holtom frå Neuro-SysMed sin .
Emne
"Challenges in running a multicentre RCT. The NO-ALS study experience." (Undervisingsspråk er engelsk.)
±ÊÃ¥³¾±ð±ô»å¾±²Ô²µ
. Fristen er 20. april kl. 11.00 dersom du vil vere med pÃ¥ lunsjen. Heilt fram til seminaret startar dersom ikkje.Â
Tid og stad
Stad: Auditoriet i Armauer Hansens Hus
±·Ã¥°ù: 22. april 2026 kl. 11:30 - 13:00 (lunsj 11:30 - 12:00).
Samandrag
There are currently no neuroprotective treatments for Amyotrophic lateral sclerosis (ALS) with a significant impact on disease progression.  Previous research by the PD Node and others has nominated NAD-replenishment therapy as a promising neuroprotective strategy against neurodegeneration. Moreover, prior to the NO-ALS study, a published small trial using a combination of the NAD-precursor nicotinamide riboside (NR) and sirtuin booster pterostilbene, showed encouraging findings in ALS. To test the potential of this strategy as a neuroprotective therapy for ALS, Neuro-SysMed Centre for Clinical Treatment Research initiated the NO-ALS trial, a phase-II, multicentre, double-blinded randomized trial of oral NR and pterostilbene inn early ALS. At this seminar, Professor Ole-Bjørn Tysnes and Study Nurse Mari Klauset Holtom from Neuro-SysMed's ALS node will discuss experiences from the NO-ALS trial, and discuss challenges in running a multicentre randomized clinical trial.Â